The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.
Regulators have approved a biotech drug made by Genentech for treating a complication related to diabetes.
A panel of Food and Drug Administration experts is recommending the approval of a drug made by Genentech for diabetic macular edema, the company said.
Regeneron and Bayer HealthCare have initiated 1-of-2 late-stage clinical trials of their aflibercept ophthalmic solution in the treatment of a complication caused by diabetic retinopathy.
Genentech, a subsidiary of Roche, reported that its eye drug helped improve vision in patients suffering from a complication caused by diabetes.
A drug designed to treat an eye condition caused by diabetes may provide a long-term option for patients, according to Alimera Sciences.
The Food and Drug Administration has granted priority review for a diabetic macular edema treatment....
An investigational treatment for a complication of diabetes that often leads to blindness worked better...
A combination of a biotech drug and laser treatment may improve vision in patients with...